Category: Interviews

At the University of Wisconsin-Madison, Dr. Rozalyn Anderson is studying one of the oldest-known and yet most powerful anti-aging interventions: caloric restriction (CR). Back in 1935, CR helped launch the entire longevity field when a pioneering study by Clive McCay and his colleagues at Cornell University demonstrated that CR without malnutrition significantly extends the lifespan...

Life Biosciences is a company co-founded by the celebrity geroscientist David Sinclair and is based on his Harvard team’s research into partial cellular reprogramming. In the heated race to translate this promising technology to the clinic, Life has emerged as one of the favorites, inching closer towards clinical trials in humans. Life is counting on...

To many people, Peter Diamandis needs no introduction, and to the rest, it's going to be a long one. To put it as concisely as possible, Peter is a serial entrepreneur and investor in several fields, from commercial space flight to longevity biotech; a visionary speaker and author of several best-selling books, including Abundance, The...

After Oculus was sold to Facebook for two billion dollars a decade ago, Michael Antonov, one of the founders, could have become a major tech investor, a popular podcaster with his own mega-theory of everything, a hedonist, or all of the above. Instead, he gravitated towards the emerging field of longevity biotech, where the uncertainties...

The Longevity Biotech Fellowship is one of the most interesting longevity-related initiatives in the last couple of years. Co-founded by Mark Hamalainen and Nathan Cheng, both well-known figures in the longevity field, LBF has been everywhere: presenting at conferences, participating in co-living projects such as Zuzalu and Vitalia, and generally connecting longevity people. The nonprofit's...

Repair Biotechnologies, a company based in Syracuse, New York, has announced findings from early research suggesting that its technology can quickly stop the advancement of atherosclerosis. While these preclinical results are in mice, this approach has the potential for treating atherosclerosis in humans. In March, the company announced that it had received positive feedback from...